Global Veterinary Animal Vaccines Market Research Report Forecast to 2025

$4,450$6,250

Clear

Description

Introduction
Veterinary vaccines are used to prevent infectious diseases caused by various agents and to provide protection to animals from various life-threatening disorders and diseases. Majority of the products are used for immunization of companion animals, ruminants, swine, poultry, and aqua animals and organisms. Veterinary vaccination has been proved helpful in the prevention of the outbreak of livestock diseases.
Factors influencing the market growth are the rising adoption rates of companion animals; increasing livestock population; frequent outbreaks of livestock diseases coupled with several advances in the technology of veterinary vaccines; and various initiatives taken by government agencies, animal associations, and prominent market players to increase awareness about the importance of animal/veterinary vaccines. On the other hand, high costs incurred for storing these vaccines to ensure potency can limit the growth of this market during the forecast period.
The global veterinary/animal vaccines market has been segmented on the basis of type, technology, and region. Based on type, the market has been divided into livestock vaccines, porcine vaccines, companion animal vaccines, poultry vaccines, and aquaculture vaccines. The livestock vaccines segment is further classified as bovine vaccines and small ruminant vaccines. The companion animal vaccines segment is further classified as canine vaccines, feline vaccines, and others. Based on technology, the global veterinary/animal vaccines market is segmented into live attenuated vaccines, inactivated vaccines, toxoid vaccines, recombinant vaccines, and others.
The global veterinary/animal vaccines market accounted for USD 6,074.05 million in 2017 and is expected to register a CAGR of 6.38 % during the forecast period.

Key Players
Some of the key players in the global veterinary/animal vaccines market are Boehringer Ingelheim International GmbH, Zoetis, Ceva, MSD & Co. Inc, Elanco, Virbac, Phibro Animal Health Corporation, Hipra., IDT Biologika GmbH, Biogenesis Bago SA, and others.
Study Objectives
• To provide a detailed analysis of the market structure along with the forecast of various segments and sub-segments of the global veterinary/animal vaccines market
• To provide insights into factors influencing and affecting market growth
• To provide historical, current, and forecast revenue of market segments based on type and technology
• To provide historical, current, and forecast revenue of market segments and sub-segments concerning regional markets and key countries
• To provide strategic profiling of key players in the market, comprehensively analyzing their market shares, core competencies, and drawing a competitive landscape for the market
• To provide economic factors, technology trends, and market trends that influence the global veterinary/animal vaccines market

Target Audience
• Animal vaccine manufacturers
• Animal healthcare product manufacturers
• Animal vaccine distributors and wholesalers
• Animal welfare associations
• Veterinary clinics and care centers
• Academic institutes and universities

Key Findings
• The global veterinary/animal vaccines market is expected to reach a value of USD 9,910.59 million by 2025 at a CAGR of 6.38%.
• On the basis of type, the livestock vaccines segment is projected to be larger, registering a CAGR of 4.87% during the forecast period.
• By technology, the live attenuated vaccines segment is expected to be larger to be valued at USD 3,637.29 million by 2025.
• On the basis of region, the market has been segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas accounted for the largest market share of 42.03% in 2017.
• Asia-Pacific is projected to be the fastest-growing market at a CAGR of 7.29% from 2018 to2025.
The report also offers a regional analysis,
• Americas
o North America
 US
 Canada
o Latin America
• Europe
o Western Europe
 Germany
 France
 UK
 Italy
 Spain
 Rest of Europe
o Eastern Europe
• Asia-Pacific
o Japan
o China
o India
o South Korea
o Australia
o Rest of Asia-Pacific
• Middle East & Africa
o Middle East
o Africa

Table of Contents

Table of Contents:

1 Report Prologue
2 Executive Summary
3 Market Introduction
3.1 Definition
3.2 Scope of the Study
3.3 Research Objective
3.4 Assumptions & Limitations
3.4.1 Assumptions
3.4.2 Limitations
3.5 Market Structure
4 Research Methodology
4.1 Research Process
4.2 Primary Research
4.3 Secondary Research
4.4 Market Size Estimation
4.5 Forecast Model
5 Market Dynamics
5.1 Introduction
5.2 Drivers
5.2.1 Increasing Number of Pet Owners
5.2.2 Growing Livestock Population and Disease Outbreaks
5.2.3 Advances in Technology underlying Veterinary Vaccines
5.2.4 Various Initiatives by Several Government Agencies, Animal Associations, and Prominent Market Players
5.3 Restraint
5.3.1 High Storage Cost associated with Veterinary Vaccines
5.4 Opportunity
5.4.1 Rising Investments to Improve Animal Health
6 Market Factor Analysis
6.1 Porter’s Five Forces Model
6.1.1 Bargaining Power of Suppliers
6.1.2 Bargaining Power of Buyers
6.1.3 Threat of New Entrants
6.1.4 Threat of Substitutes
6.1.5 Rivalry
6.2 Supply Chain Analysis
6.2.1 R&D and Development
6.2.2 Manufacturing
6.2.3 Distribution & Sales
6.2.4 Post-Sales Monitoring
7 Global Veterinary/Animal Vaccines Market, by Type
7.1 Introduction
7.1.1 Livestock Vaccines
7.1.2 Porcine Vaccines
7.1.3 Companion Animal Vaccines
7.1.4 Poultry Vaccines
7.1.5 Aquaculture Vaccines
8 Global Veterinary/Animal Vaccines Market, by Technology
8.1 Introduction
8.1.1 Live Attenuated Vaccines
8.1.2 Inactivated Vaccines
8.1.3 Recombinant Vaccines
8.1.4 Toxoid Vaccines
9 Global Veterinary/Animal Vaccines Market, by Region
9.1 Introduction
9.2 Americas
9.2.1 North America
9.2.1.1 US
9.2.1.2 Canada
9.2.2 South America
9.3 Europe
9.3.1 Western Europe
9.3.1.1 France
9.3.1.2 Germany
9.3.1.3 UK
9.3.1.4 Spain
9.3.1.5 Italy
9.3.1.6 Rest of Western Europe
9.3.2 Eastern Europe
9.4 Asia-Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 Republic of Korea
9.4.6 Rest of Asia-Pacific
9.5 Middle East and Africa
9.5.1 Middle East
9.5.2 Africa
10 Competitive Landscape
10.1 Introduction
11 Company Profiles
11.1 Boehringer Ingelheim International GmbH
11.1.1 Company Overview
11.1.2 Financial Overview
11.1.3 Products/Services Offered
11.1.4 Key Developments
11.1.5 SWOT Analysis
11.1.6 Key Strategies
11.2 Zoetis
11.2.1 Company Overview
11.2.2 Financial Overview
11.2.3 Products/Services Offered
11.2.4 Key Developments
11.2.5 SWOT Analysis
11.2.6 Key Strategies
11.3 Ceva
11.3.1 Company Overview
11.3.2 Financial Overview
11.3.3 Products/Services Offered
11.3.4 Key Developments
11.3.5 SWOT Analysis
11.3.6 Key Strategies
11.4 MSD & Co. Inc.
11.4.1 Company Overview
11.4.2 Financial Overview
11.4.3 Products/Services Offered
11.4.4 Key Developments
11.4.5 SWOT Analysis
11.4.6 Key Strategies
11.5 Elanco
11.5.1 Company Overview
11.5.2 Financial Overview
11.5.3 Products/Services Offered
11.5.4 Key Developments
11.5.5 SWOT Analysis
11.5.6 Key Strategies
11.6 Virbac
11.6.1 Company Overview
11.6.2 Financial Overview
11.6.3 Products/Services Offered
11.6.4 Key Developments
11.6.5 SWOT Analysis
11.6.6 Key Strategies
11.7 Phibro Animal Health Corporation.
11.7.1 Company Overview
11.7.2 Financial Overview
11.7.3 Products/Services Offered
11.7.4 Key Developments
11.7.5 SWOT Analysis
11.7.6 Key Strategies
11.8 Hipra
11.8.1 Company Overview
11.8.2 Financial Overview
11.8.3 Products/Services Offered
11.8.4 Key Developments
11.8.5 SWOT Analysis
11.8.6 Key Strategies
11.9 IDT Biologika GmbH
11.9.1 Company Overview
11.9.2 Financial Overview
11.9.3 Products/Services Offered
11.9.4 Key Developments
11.9.5 SWOT Analysis
11.9.6 Key Strategies
11.1 Biogenesis Bago SA
11.10.1 Company Overview
11.10.2 Financial Overview
11.10.3 Products/Services Offered
11.10.4 Key Developments
11.10.5 SWOT Analysis
11.10.6 Key Strategies
12 Appendix
12.1 Discussion Blue Print

Additional information

Publisher

Geography Covered

Date Published

Pages

Format